The role of galectin-3 in the kidneys

International Journal of Molecular Sciences

Volumn 17, Issue 4, 2016, Pages

  Chen, Szu Chia ^a,b,c   Kuo, Po Lin ^a,d  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c KAOHSIUNG MUNICIPAL HSIAO KANG HOSPITAL   (Taiwan)

^d NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

Clinical renal disease; Galectin 3; Kidney; Nephrogenesis

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; GALECTIN 3; HERMES ANTIGEN; IMMUNOGLOBULIN A; ROSIGLITAZONE;

ACUTE KIDNEY FAILURE; APOPTOSIS; CELL DAMAGE; CELL REGENERATION; CHRONIC ALLOGRAFT NEPHROPATHY; CHRONIC KIDNEY DISEASE; DIABETIC NEPHROPATHY; GENE EXPRESSION; GLOMERULOPATHY; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEMODIALYSIS; HUMAN; IMMUNOFLUORESCENCE; KIDNEY DISEASE; KIDNEY FIBROSIS; KIDNEY TRANSPLANTATION; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROALBUMINURIA; MORPHOGENESIS; MOUSE MODEL; NEPHROTIC SYNDROME; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); REPERFUSION INJURY; REVIEW; ANIMAL; BLOOD; KIDNEY; KIDNEY DISEASES; METABOLISM; PATHOLOGY;

ANIMALS; GALECTIN 3; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; KIDNEY; KIDNEY DISEASES; KIDNEY TRANSPLANTATION;

EID: 84963727593     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms17040565     Document Type: Review

References (55)

1. Barondes, S.H.; Cooper, D.N.; Gitt, M.A.; Leffler, H. Galectins. Structure and function of a large family of animal lectins. J. Biol. Chem. 1994, 269, 20807-20810. [PubMed]
2. Cummings, R.D.; Liu, F.T. Galectins. In Essentials of Glycobiology, 2nd ed.; Varki, A., Cummings, R.D., Esko, J.D., Freeze, H.H., Stanley, P., Bertozzi, C.R., Hart, G.W., Etzler, M.E., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2009.
3. Kasai, K.; Hirabayashi, J. Galectins: A family of animal lectins that decipher glycocodes. J. Biochem. 1996, 119, 1-8. [CrossRef] [PubMed]
4. Davidson, P.J.; Davis, M.J.; Patterson, R.J.; Ripoche, M.A.; Poirier, F.; Wang, J.L. Shuttling of galectin-3 between the nucleus and cytoplasm. Glycobiology 2002, 12, 329-337. [CrossRef] [PubMed]
5. Hsu, D.K.; Liu, F.T. Regulation of cellular homeostasis by galectins. Glycoconj. J. 2004, 19, 507-515. [CrossRef] [PubMed]
6. Ochieng, J.; Furtak, V.; Lukyanov, P. Extracellular functions of galectin-3. Glycoconj. J. 2004, 19, 527-535. [CrossRef] [PubMed]
7. Dumic, J.; Dabelic, S.; Flogel, M. Galectin-3: An open-ended story. Biochim. Biophys. Acta 2006, 1760, 616-635. [CrossRef] [PubMed]
8. De Boer, R.A.; Voors, A.A.; Muntendam, P.; van Gilst, W.H.; van Veldhuisen, D.J. Galectin-3: A novel mediator of heart failure development and progression. Eur. J. Heart Fail. 2009, 11, 811-817. [CrossRef] [PubMed]
9. Henderson, N.C.; Sethi, T. The regulation of inflammation by galectin-3. Immunol. Rev. 2009, 230, 160-171. [CrossRef] [PubMed]
10. Sakaki, M.; Fukumori, T.; Fukawa, T.; Elsamman, E.; Shiirevnyamba, A.; Nakatsuji, H.; Kanayama, H.O. Clinical significance of Galectin-3 in clear cell renal cell carcinoma. J. Med. Investig. 2010, 57, 152-157. [CrossRef]
11. Straube, T.; Elli, A.F.; Greb, C.; Hegele, A.; Elsasser, H.P.; Delacour, D.; Jacob, R. Changes in the expression and subcellular distribution of galectin-3 in clear cell renal cell carcinoma. J. Exp. Clin. Cancer Res. 2011, 30, 89. [CrossRef] [PubMed]
12. Menini, S.; Iacobini, C.; Blasetti Fantauzzi, C.; Pesce, C.M.; Pugliese, G. Role of galectin-3 in obesity and impaired glucose homeostasis. Oxid. Med. Cell. Longev. 2016, 2016, 9618092. [CrossRef] [PubMed]
13. Dhirapong, A.; Lleo, A.; Leung, P.; Gershwin, M.E.; Liu, F.T. The immunological potential of galectin-1 and -3. Autoimmun. Rev. 2009, 8, 360-363. [CrossRef] [PubMed]
14. Feldman, C. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J. Lab. Clin. Med. 2004, 143, 269-283. [CrossRef] [PubMed]
15. Bichara, M.; Attmane-Elakeb, A.; Brown, D.; Essig, M.; Karim, Z.; Muffat-Joly, M.; Micheli, L.; Eude-Le Parco, I.; Cluzeaud, F.; Peuchmaur, M et al. Exploring the role of galectin 3 in kidney function: A genetic approach. Glycobiology 2006, 16, 36-45. [CrossRef] [PubMed]
16. Winyard, P.J.; Bao, Q.; Hughes, R.C.; Woolf, A.S. Epithelial galectin-3 during human nephrogenesis and childhood cystic diseases. J. Am. Soc. Nephrol. 1997, 8, 1647-1657. [PubMed]
17. Bullock, S.L.; Johnson, T.M.; Bao, Q.; Hughes, R.C; Winyard, P.J.; Woolf, A.S. Galectin-3 modulates ureteric bud branching in organ culture of the developing mouse kidney. J. Am. Soc. Nephrol. 2001, 12, 515-523. [PubMed]
18. Iacobini, C.; Menini, S.; Oddi, G.; Ricci, C.; Amadio, L.; Pricci, F.; Olivieri, A.; Sorcini, M.; di Mario, U.; Pesce, C.; Pugliese, G. Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: Evidence for a protective role of galectin-3 as an AGE receptor. FASEB J. 2004, 18, 1773-1775. [CrossRef] [PubMed]
19. Nishiyama, J.; Kobayashi, S.; Ishida, A.; Nakabayashi, I.; Tajima, O.; Miura, S.; Katayama, M.; Nogami, H. Up-regulation of galectin-3 in acute renal failure of the rat. Am. J. Pathol. 2000, 157, 815-823. [CrossRef]
20. Lohr, M.; Kaltner, H.; Lensch, M.; Andre, S.; Sinowatz, F.; Gabius, H.J. Cell-type-specific expression of murine multifunctional galectin-3 and its association with follicular atresia/luteolysis in contrast to pro-apoptotic galectins-1 and -7. Histochem. Cell Biol. 2008, 130, 567-581. [CrossRef] [PubMed]
21. Diamond, J.R. Macrophages and progressive renal disease in experimental hydronephrosis. Am. J. Kidney Dis. 1995, 26, 133-140. [CrossRef]
22. Henderson, N.C.; Mackinnon, A.C.; Farnworth, S.L.; Kipari, T.; Haslett, C.; Iredale, J.P.; Liu, F.T.; Hughes, J.; Sethi, T. Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis. Am. J. Pathol. 2008, 172, 288-298. [CrossRef] [PubMed]
23. Okamura, D.M.; Pasichnyk, K.; Lopez-Guisa, J.M.; Collins, S.; Hsu, D.K.; Liu, F.T.; Eddy, A.A. Galectin-3 preserves renal tubules and modulates extracellular matrix remodeling in progressive fibrosis. Am. J. Physiol. Ren. Physiol. 2011, 300, F245-F253. [CrossRef] [PubMed]
24. Pugliese, G.; Pricci, F.; Iacobini, C.; Leto, G.; Amadio, L.; Barsotti, P.; Frigeri, L.; Hsu, D.K.; Vlassara, H.; Liu, F.T et al. Accelerated diabetic glomerulopathy in galectin-3/AGE receptor 3 knockout mice. FASEB J. 2001, 15, 2471-2479. [CrossRef] [PubMed]
25. Vansthertem, D.; Cludts, S.; Nonclercq, D.; Gossiaux, A.; Saussez, S.; Legrand, A.; Gabius, H.J.; Toubeau, G. Immunohistochemical localization of galectins-1 and -3 and monitoring of tissue galectin-binding sites during tubular regeneration after renal ischemia reperfusion in the rat. Histol. Histopathol. 2010, 25, 1417-1429. [PubMed]
26. Fernandes Bertocchi, A.P.; Campanhole, G; Wang, P.H.; Goncalves, G.M.; Damiao, M.J.; Cenedeze, M.A.; Beraldo, F.C.; dos Reis, M.A.; Mazzali, M et al. A Role for galectin-3 in renal tissue damage triggered by ischemia and reperfusion injury. Transpl. Int. 2008, 21, 999-1007. [CrossRef] [PubMed]
27. Kikuchi, Y.; Kobayashi, S.; Hemmi, N.; Ikee, R.; Hyodo, N.; Saigusa, T.; Namikoshi, T.; Yamada, M.; Suzuki, S.; Miura, S. Galectin-3-positive cell infiltration in human diabetic nephropathy. Nephrol. Dial. Transplant. 2004, 19, 602-607. [CrossRef] [PubMed]
28. Kang, E.H.; Moon, K.C.; Lee, E.Y.; Lee, Y.J.; Lee, E.B.; Ahn, C.; Song, Y.W. Renal expression of galectin-3 in systemic lupus erythematosus patients with nephritis. Lupus 2009, 18, 22-28. [CrossRef] [PubMed]
29. Sharma, U.C.; Pokharel, S.; van Brakel, T.J.; van Berlo, J.H.; Cleutjens, J.P.; Schroen, B.; Andre, S.; Crijns, H.J.; Gabius, H.J.; Maessen, J et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110, 3121-3128. [CrossRef] [PubMed]
30. Yu, L.; Ruifrok, W.P.; Meissner, M.; Bos, E.M.; van Goor, H.; Sanjabi, B.; van der Harst, P.; Pitt, B.; Goldstein, I.J.; Koerts, J.A et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 2013, 6, 107-117. [CrossRef] [PubMed]
31. Schroen, B.; Heymans, S.; Sharma, U.; Blankesteijn, W.M.; Pokharel, S.; Cleutjens, J.P.; Porter, J.G.; Evelo, C.T.; Duisters, R.; van Leeuwen, R.E et al. Thrombospondin-2 is essential for myocardial matrix integrity: Increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 2004, 95, 515-522. [CrossRef] [PubMed]
32. Calvier, L.; Miana, M.; Reboul, P.; Cachofeiro, V.; Martinez-Martinez, E.; de Boer, R.A.; Poirier, F.; Lacolley, P.; Zannad, F.; Rossignol, P et al. Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler. Thromb. Vasc. Biol. 2013, 33, 67-75. [CrossRef] [PubMed]
33. Tang, W.H.; Shrestha, K.; Shao, Z.; Borowski, A.G.; Troughton, R.W.; Thomas, J.D.; Klein, A.L. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival. Am. J. Cardiol. 2011, 108, 385-390. [CrossRef] [PubMed]
34. Lok, D.J.; van der Meer, P.; de la Porte, P.W.; Lipsic, E.; vanWijngaarden, J.; Hillege, H.L.; van Veldhuisen, D.J. Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: Data from the DEAL-HF study. Clin. Res. Cardiol. 2010, 99, 323-328. [CrossRef] [PubMed]
35. Zamora, E.; Lupon, J.; de Antonio, M.; Galan, A.; Domingo, M.; Urrutia, A.; Troya, M.; Bayes-Genis, A. Renal function largely influences Galectin-3 prognostic value in heart failure. Int. J. Cardiol. 2014, 177, 171-177. [CrossRef] [PubMed]
36. Gopal, D.M.; Kommineni, M.; Ayalon, N.; Koelbl, C.; Ayalon, R.; Biolo, A.; Dember, L.M.; Downing, J.; Siwik, D.A.; Liang, C.S et al. Relationship of plasma galectin-3 to renal function in patients with heart failure: Effects of clinical status, pathophysiology of heart failure, and presence or absence of heart failure. J. Am. Heart Assoc. 2012, 1, e000760. [CrossRef] [PubMed]
37. Meijers, W.C.; van der Velde, A.R.; Ruifrok, W.P.; Schroten, N.F.; Dokter, M.M.; Damman, K.; Assa, S.; Franssen, C.F.; Gansevoort, R.T.; van Gilst, W.H et al. Renal handling of galectin-3 in the general population, chronic heart failure, and hemodialysis. J. Am. Heart Assoc. 2014, 3, e000962. [CrossRef] [PubMed]
38. Ensrud, K.E.; Lui, L.Y.; Taylor, B.C.; Ishani, A.; Shlipak, M.G.; Stone, K.L.; Cauley, J.A.; Jamal, S.A.; Antoniucci, D.M.; Cummings, S.R. Renal function and risk of hip and vertebral fractures in older women. Arch. Intern. Med. 2007, 167, 133-139. [CrossRef] [PubMed]
39. McClellan, W.M.; Flanders, W.D. Risk factors for progressive chronic kidney disease. J. Am. Soc. Nephrol. 2003, 14, S65-S70. [CrossRef] [PubMed]
40. Perkovic, V.; Cass, A.; Patel, A.A.; Suriyawongpaisal, P.; Barzi, F.; Chadban, S.; Macmahon, S.; Neal, B. High prevalence of chronic kidney disease in Thailand. Kidney Int. 2008, 73, 473-479. [CrossRef] [PubMed]
41. Tanaka, H.; Shiohira, Y.; Uezu, Y.; Higa, A.; Iseki, K. Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney. Int. 2006, 69, 369-374. [CrossRef] [PubMed]
42. Weiner, D.E.; Tighiouart, H.; Amin, M.G.; Stark, P.C.; MacLeod, B.; Griffith, J.L.; Salem, D.N.; Levey, A.S.; Sarnak, M.J. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: A pooled analysis of community-based studies. J. Am. Soc. Nephrol. 2004, 15, 1307-1315. [CrossRef] [PubMed]
43. De Zeeuw, D.; Ramjit, D.; Zhang, Z.; Ribeiro, A.B.; Kurokawa, K.; Lash, J.P.; Chan, J.; Remuzzi, G.; Brenner, B.M.; Shahinfar, S. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney Int. 2006, 69, 1675-1682. [CrossRef] [PubMed]
44. O'Seaghdha, C.M.; Hwang, S.J.; Ho, J.E.; Vasan, R.S.; Levy, D.; Fox, C.S. Elevated galectin-3 precedes the development of CKD. J. Am. Soc. Nephrol. 2013, 24, 1470-1477. [CrossRef] [PubMed]
45. Iacobini, C.; Amadio, L.; Oddi, G.; Ricci, C.; Barsotti, P.; Missori, S.; Sorcini, M.; di Mario, U.; Pricci, F.; Pugliese, G. Role of galectin-3 in diabetic nephropathy. J. Am. Soc. Nephrol. 2003, 14, S264-S270. [CrossRef] [PubMed]
46. Drechsler, C.; Delgado, G.; Wanner, C.; Blouin, K.; Pilz, S.; Tomaschitz, A.; Kleber, M.E.; Dressel, A.; Willmes, C.; Krane, V et al. Galectin-3, renal function, and clinical outcomes: Results from the LURIC and 4D studies. J. Am. Soc. Nephrol. 2015, 26, 2213-2221. [CrossRef] [PubMed]
47. De Boer, R.A.; Lok, D.J.; Jaarsma, T.; van der Meer, P.; Voors, A.A.; Hillege, H.L.; van Veldhuisen, D.J. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Ann. Med. 2011, 43, 60-68. [CrossRef] [PubMed]
48. De Boer, R.A.; van Veldhuisen, D.J.; Gansevoort, R.T.; Muller Kobold, A.C.; van Gilst, W.H.; Hillege, H.L.; Bakker, S.J.; van der Harst, P. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 2012, 272, 55-64. [CrossRef] [PubMed]
49. Arend, S.M.; Mallat, M.J.; Westendorp, R.J.; van der Woude, F.J.; van Es, L.A. Patient survival after renal transplantation; more than 25 years follow-up. Nephrol. Dial. Transplant. 1997, 12, 1672-1679. [PubMed]
50. Tan, R.; Liu, X.; Wang, J.; Lu, P.; Han, Z.; Tao, J.; Yin, C.; Gu, M. Alternations of galectin levels after renal transplantation. Clin. Biochem. 2014, 47, 83-88. [CrossRef] [PubMed]
51. Dang, Z.; MacKinnon, A.; Marson, L.P.; Sethi, T. Tubular atrophy and interstitial fibrosis after renal transplantation is dependent on galectin-3. Transplantation 2012, 93, 477-484. [CrossRef] [PubMed]
52. Sasaki, S.; Bao, Q.; Hughes, R.C. Galectin-3 modulates rat mesangial cell proliferation and matrix synthesis during experimental glomerulonephritis induced by anti-Thy1.1 antibodies. J. Pathol. 1999, 187, 481-489. [CrossRef]
53. Sun, Z.L.; Ma, C.J.; Jin, H.; Yuan, Y.; Liu, N.F. Effects of advanced glycosylation end products and rosiglitazone on the expression and secretion of galectin-3 in human renal mesangial cells. Chin. Med. J. 2009, 122, 1067-1071. [PubMed]
54. Kolatsi-Joannou, M.; Price, K.L.; Winyard, P.J.; Long, D.A. Modified citrus pectin reduces galectin-3 expression and disease severity in experimental acute kidney injury. PLoS ONE 2011, 6, e18683. [CrossRef] [PubMed]
55. La Jolla begins Phase IIb trial of GCS-100 to treat advanced CKD. Available online: http://www.drugdevelopment-technology.com/news/newsla-jolla-begins-phase-iib-trial-of-gcs-100-totreat-advanced-ckd-4535972 (accessed on 12 April 2016).